Traditional pharmaceutical manufacturing makes medicines in batches.
Some cell therapies make a medicine from a patient’s own cells.
That changes the factory logic completely.
Did you know that Singapore regulates cell, tissue and gene therapy products as a distinct health-product category and now has manufacturing, clinical and regulatory capability around these advanced therapies?
This article targets cell therapy Singapore, gene therapy Singapore, advanced therapy manufacturing Singapore, CTGTP Singapore and cell therapy manufacturing Singapore.
Official information was checked on 4 October 2026. This is an industry explainer, not medical advice.
Did You Know? HSA Regulates Cell, Tissue and Gene Therapy Products as a Distinct Category
HSA regulates the registration, manufacture, import and supply of Cell, Tissue and Gene Therapy Products, or CTGTPs, in Singapore.
Official reference: HSA — Cell, Tissue and Gene Therapy Products.
The separate framework reflects the fact that living cells and genetic modifications create different manufacturing and safety questions from conventional tablets.
What Is a Cell Therapy?
A cell therapy uses living cells as the therapeutic product or as a major part of it.
Those cells may come from the patient, another donor or an engineered cell line depending on the therapy.
The medicine is biologically active in a way that makes manufacturing conditions especially important.
What Is Gene Therapy?
Gene therapy changes genetic material in cells to treat or prevent disease.
Some therapies deliver genetic material directly.
Others modify cells outside the body and then return those cells to the patient.
Manufacturing can therefore include viral vectors, cell expansion and highly controlled handling.
Autologous Therapy Creates a One-Patient Supply Chain
In an autologous cell therapy, the patient’s own cells can become the starting material.
The material is collected, transported to a manufacturing facility, processed and returned for administration.
The batch may effectively belong to one person.
Identity control becomes a manufacturing-critical requirement.
Worked Example: The Batch Is the Patient
Imagine a conventional factory produces 10,000 identical vials from one batch.
An autologous therapy may instead process 100 separate patient-specific batches.
Mixing up two labels is therefore not a minor inventory error.
It can become a direct patient-safety failure.
Chain of Identity Is Central
Manufacturers need to know whose cells are being processed at every stage.
Barcodes, digital records, custody procedures and reconciliation help preserve that identity.
The data record is inseparable from the biological product.
Advanced therapy manufacturing is partly an information-management business.
GMP Is Mandatory for More Than Minimally Manipulated CTGTPs
HSA’s current licensing guidance states that manufacturers handling CTGTPs that are more than minimally manipulated require the relevant manufacturer’s licence, with Good Manufacturing Practice compliance mandatory.
Official reference: HSA — CTGTP Manufacturer Licensing.
The manufacturing facility therefore needs pharmaceutical-grade quality systems.
Minimally Manipulated Products Follow a Different Route
HSA distinguishes minimally manipulated CTGTPs from more extensively manipulated products.
Some minimally manipulated CTGTP activities require notification rather than the same licence structure applied to higher-risk products.
Official reference: HSA — CTGTP Dealer Licence Overview.
Regulatory intensity follows the product and process.
Singapore Has Local Cell Therapy Manufacturing Capability
SCG Cell Therapy established a Singapore research and pilot cGMP manufacturing hub for cell therapy, including closed and automated manufacturing technologies.
Official reference: EDB — SCG Cell Therapy Singapore Hub.
The ecosystem connects research, clinical development and manufacturing.
Singapore’s Biopharma Base Now Includes Cell Therapies
EDB’s current biopharma page says Singapore hosts more than 60 manufacturing sites across small-molecule APIs, biologics and emerging modalities including cell therapies.
Official reference: EDB — Biotechnology and Pharmaceuticals.
Advanced therapies are becoming part of the broader biomanufacturing cluster.
Closed and Automated Manufacturing Reduces Manual Exposure
Cell processing traditionally involves many manual steps inside controlled environments.
Closed systems and automation can reduce operator intervention and contamination opportunities.
They also create new dependence on sensors, software and validated equipment.
Automation changes the risk profile rather than eliminating risk.
Worked Example: Capacity Is Measured Differently
A conventional bioreactor may be measured in litres.
A cell-therapy factory may care more about how many patient batches can be processed per week.
Two facilities with the same floor area can therefore have very different economic capacity.
Advanced-therapy manufacturing needs different productivity metrics.
Viral Vectors Are a Critical Input
Many gene therapies use viral vectors to deliver genetic material.
Vector production can itself be a specialised biomanufacturing process.
Supply shortages or quality problems can delay therapy programmes.
The advanced-therapy industry therefore contains multiple linked manufacturing layers.
Cryogenic Logistics Can Be Part of the Therapy
Cells may need tightly controlled refrigerated or frozen transport.
The collection, factory and hospital need a validated chain of custody and temperature control.
See Making Singapore Rich | Cold-Chain Logistics, Refrigeration and Perishable Trade.
The logistics route becomes part of the manufacturing process.
Advanced Therapies Connect Clinical Trials to Manufacturing
A trial product may be made for a small number of patients.
If the therapy works, manufacturing needs to scale without changing product quality.
See Making Singapore Rich | Clinical Trials, Contract Research and Biomedical Translation.
Translation is both scientific and industrial.
Regulatory Collaboration Is Expanding
In May 2026, HSA and China’s NMPA renewed a regulatory collaboration agreement that explicitly expanded cooperation into emerging areas including cell, tissue and gene therapy products.
Official reference: HSA — Singapore-China Regulatory Collaboration.
Regulatory convergence can reduce duplicated development friction across markets.
The Risk: Batch Failure Is Personal
In patient-specific therapy, a failed batch may not be replaceable from warehouse inventory.
The patient may need another collection procedure or may not have time to wait.
Manufacturing reliability becomes part of clinical urgency.
The Risk: Raw Material Variability
Patient-derived cells can vary significantly from one person to another.
The manufacturing process must handle biological variation while still meeting release specifications.
Unlike conventional chemistry, the starting material is not always standardised.
The Risk: Cost Per Patient Can Be Very High
Small batches, skilled labour, specialised facilities and complex quality testing can make advanced therapies expensive.
Automation and platform processes can improve economics.
The sector still faces a major challenge in scaling affordability.
The Risk: Manufacturing Changes Can Affect Clinical Performance
Changing media, equipment or process timing can alter the cells.
Manufacturing changes therefore need careful comparability assessment.
The process can influence the therapeutic product directly.
Quality-by-design is especially important.
Advanced Therapies Connect to Genomics
Gene therapies and personalised cell therapies rely on molecular understanding and genomic tools.
See Making Singapore Rich | Genomics, Precision Medicine and Bioinformatics.
Precision medicine creates demand for precision manufacturing.
Advanced Therapies Connect to Laboratory Automation
Cell counting, flow cytometry, sequencing and release testing generate large amounts of laboratory work.
See Making Singapore Rich | Scientific Instruments, Laboratory Automation and Analytical Testing.
The therapy factory is also a testing factory.
Education Builds Advanced-Therapy Capability
The sector needs cell biologists, process engineers, GMP specialists, quality teams, automation engineers and regulatory professionals.
Students need biology, chemistry, data and manufacturing discipline.
See Making Singapore Rich | Education, Skills and Human Capital.
A Guided Classroom Investigation
Give students two fictional manufacturing models: one produces 10,000 identical doses; the other produces one patient-specific batch per person.
Ask which one needs stricter identity tracking.
The exercise teaches why manufacturing design follows the product.
Independent Practice: Central Factory or Hospital-Based Production?
A fictional therapy can be produced in one central plant or several smaller hospital-adjacent facilities.
Which is better?
Students should compare scale, logistics, quality control, turnaround time and regulatory oversight.
The learning goal is manufacturing-network design.
What Progress Should Look Like
A stronger advanced-therapy economy should create more GMP manufacturing capacity, automated cell-processing platforms, reliable cryogenic logistics, regulatory expertise and stronger links between clinical research and commercial production.
A stronger learner should distinguish cells from conventional drug batches, chain of identity from ordinary inventory control and research success from scalable manufacturing.
Frequently Asked Questions
What is CTGTP?
It stands for Cell, Tissue and Gene Therapy Products, a distinct category regulated by HSA in Singapore.
Do CTGTP manufacturers need licences?
Manufacturers of more-than-minimally-manipulated CTGTPs generally need the applicable licence and must comply with GMP requirements. Minimally manipulated products follow a different notification and regulatory route.
Does Singapore have cell-therapy manufacturing?
Yes. Singapore hosts cell-therapy manufacturing and R&D capability, including SCG Cell Therapy’s local cGMP hub.
How do advanced therapies make Singapore richer?
They create high-value manufacturing, clinical-development, cold-chain, regulatory and biomedical-engineering capabilities around some of medicine’s most advanced products.
Helpful Reading and Singapore Graph Connections
- HSA — Cell, Tissue and Gene Therapy Products
- HSA — CTGTP Manufacturing, Import and Wholesale
- EDB — Biotechnology and Pharmaceuticals
- Making Singapore Rich | Biologics Manufacturing, CDMO and Bioprocessing
Making Singapore Rich: Manufacture the Medicine One Patient at a Time
Did you know that some of the world’s most advanced medicines behave more like personalised manufacturing orders than conventional pharmaceutical batches?
The patient supplies the starting material.
The factory transforms the cells.
Quality systems preserve identity.
Logistics returns the product.
Singapore becomes richer when clinical science, manufacturing and regulation can handle this new production model safely.
The therapy is biological.
The industrial capability makes the biology reproducible.